SCHEMBL25516477

SCHEMBL25516477

CC(C)CCc1ccc(C(=O)C(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
DBH P09172 1/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
DPP4 P27487 6/20 0.42
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
MMP12 P39900 1/20 0.41
MMP13 P45452 1/20 0.41
HPGD P15428 1/20 0.40
HSP90AA1 P07900 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3685675 0.88 KDM4E (0.50) KDM4EDBHGAARECQLKMT2A
SCHEMBL25522757 0.85 GRIN2D (0.42) GRIN2DGRIN2AGRIN2BGRIN2CKMT2A
SCHEMBL25523371 0.85 KDM4E (0.42) KDM4EDBHGAARECQLKMT2A
SCHEMBL25523231 0.85 DPP4 (0.43) GRIN2DGRIN2AGRIN2BGRIN2CKMT2A
SCHEMBL104594 0.82 GRIN2D (0.57) KDM4EGAARECQLGRIN2DGRIN2A
SCHEMBL9666038 0.82 PLK1 (0.56) KDM4EDBHGAARECQLKMT2A
SCHEMBL12018041 0.82 KMT2A (0.57) GAAGRIN2DGRIN2AGRIN2BGRIN2C
SCHEMBL340019 0.82 CYP4A11 (0.61) KDM4EDBHGAARECQLCYP4F2
SCHEMBL3977627 0.81 KDM4E (0.44) KDM4EDBHGAARECQLKMT2A
SCHEMBL20630223 0.81 KMT2A (0.55) KDM4EDBHGAARECQLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed
US-9012603-B2 Peptides that block the binding of IgG to FcRn BIOGEN IDEC HEMOPHILIA INC. (US) 2015-04-21 US disclosed
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn SYNTONIX PHARMACEUTICALS, INC. 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF HDAC6, PSMG3, PSMB2 KDM4E 1954/4885DBH 1491/4885GAA 194/4885
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn FCGRT, FCGR3B, FCGR1A KDM4E 4111/4885DBH 4608/4885GAA 3095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.